The US regulator has called for new eye-related warnings on GLP-1 drug labels, but Indian safety data remains limited
US FDA flags blindness risk from GLP-1 drugs: What patients should know
BU
Business Standard - LatestBy Sarjna Rai
EXECUTIVE SUMMARY
The US regulator has called for new eye-related warnings on GLP-1 drug labels, but Indian safety data remains limited
Key Takeaways
- US FDA flags blindness risk from GLP-1 drugs: What patients should know.
Read Complete Original Article
Published originally on Business Standard - Latest
